

Patient Name: 최정인
Gender: F
Sample ID: N26-62

Primary Tumor Site: breast
Collection Date: 2025.04.05

Sample Cancer Type: Breast Cancer

Table of Contents	Page	Report Highlights
Variant Details	1	1 Relevant Biomarkers
Biomarker Descriptions	2	0 Therapies Available
Relevant Therapy Summary	5	1 Clinical Trials

Relevant Breast Cancer Findings

Gene	Finding
BRCA1	None detected
ERBB2	None detected

Genomic Alteration	Finding
Tumor Mutational Burden	4.74 Mut/Mb measured

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	PALB2 p.(T397Sfs*3) c.1190_1191delCA partner and localizer of BRCA2 Allele Frequency: 58.72% Locus: chr16:23646675 Transcript: NM_024675.4	None*	None*	1

* Public data sources included in relevant therapies: FDA1, NCCN, EMA2, ESMO

* Public data sources included in prognostic and diagnostic significance: NCCN, ESMO

Line of therapy: I: First-line therapy, II+: Other line of therapy

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Prevalent cancer biomarkers without relevant evidence based on included data sources

Microsatellite stable, HLA-A deletion, NQO1 p.(P187S) c.559C>T, Tumor Mutational Burden

Variant Details

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
PALB2	p.(T397Sfs*3)	c.1190_1191delCA	.	chr16:23646675	58.72%	NM_024675.4	frameshift Deletion

Variant Details (continued)

DNA Sequence Variants (continued)

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
NQO1	p.(P187S)	c.559C>T	.	chr16:69745145	52.33%	NM_000903.3	missense
ALK	p.(S1216R)	c.3648C>A	.	chr2:29436945	11.31%	NM_004304.5	missense
KIT	p.(S929*)	c.2786C>G	.	chr4:55603430	50.45%	NM_000222.3	nonsense
BRCA2	p.(Y828H)	c.2482T>C	.	chr13:32910974	49.67%	NM_000059.4	missense
TSC2	p.(D616H)	c.1846G>C	.	chr16:2121517	11.67%	NM_000548.5	missense
AXIN2	p.(P736S)	c.2206C>T	.	chr17:63531775	51.18%	NM_004655.4	missense

Copy Number Variations

Gene	Locus	Copy Number	CNV Ratio
HLA-A	chr6:29910229	0	0.54

Biomarker Descriptions

PALB2 p.(T397Sfs*3) c.1190_1191delCA

partner and localizer of BRCA2

Background: The PALB2 gene encodes the partner and localizer of BRCA2 protein that binds to and promotes intranuclear localization of the breast cancer 2 early onset (BRCA2) protein¹⁰. Also known as FANCN, PALB2 belongs to the Fanconi Anemia (FA) complementation group of proteins that also include FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM. FA genes are tumor suppressors that play a role in interstrand cross-link (ICL) DNA repair through homologous recombination repair (HRR) of double-strand breaks (DSB) and nucleotide excision repair (NER)¹¹. Loss of function mutations of genes in the FA family and HRR pathway, including PALB2, can result in the BRCAness phenotype, characterized by a defect in the HRR pathway, mimicking BRCA1 or BRCA2 loss^{12,13}. Germline mutations in FA genes lead to Fanconi Anemia, a condition characterized by chromosomal instability and congenital abnormalities including bone marrow failure and cancer predisposition^{14,15}. Specifically, biallelic germline mutations resulting in PALB2 loss of function confer a predisposition to pediatric malignancies^{16,17}. Additionally, monoallelic germline mutations in PALB2 have been associated with an increased risk of developing breast cancer^{16,18}.

Alterations and prevalence: Somatic alterations in PALB2 include missense or truncating mutations and are observed in 2-6% of melanoma, uterine, bladder, breast, lung, stomach and colorectal cancers⁸.

Potential relevance: The PARP inhibitor, olaparib¹⁹ is approved (2020) for metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious, germline or somatic mutations in HRR genes that includes PALB2. Additionally, talazoparib²⁰ in combination with enzalutamide is approved (2023) for mCRPC with mutations in HRR genes that includes PALB2. In a phase II trial of patients with metastatic, castration-resistant prostate cancer, one patient exhibiting a somatic PALB2 frameshift mutation exhibited durable response to olaparib for 39 weeks^{21,22}. However, olaparib resistance was observed following 9-months of treatment due to the emergence of a secondary deletion which restored the PALB2 reading frame, a resistance mechanism similar to that observed in PARPi treated BRCA mutated patients^{22,23}. Follow-up genomic studies have further shown that although PALB2-mutated cancers can respond to PARP inhibition, they frequently develop resistance through similar PALB2 reversion events^{24,25,26}. In 2022, the FDA granted fast track designation to the small molecule inhibitor, pidnarulex²⁷, for BRCA1/2, PALB2, or other homologous recombination deficiency (HRD) mutations in breast and ovarian cancers. Rucaparib is recommended as a maintenance therapy for germline or somatic PALB2 mutations in metastatic pancreatic cancer²⁸.

Microsatellite stable

Background: Microsatellites are short tandem repeats (STR) of 1 to 6 bases of DNA between 5 to 50 repeat units in length. There are approximately 0.5 million STRs that occupy 3% of the human genome²⁹. Microsatellite instability (MSI) is defined as a change in the length of a microsatellite in a tumor as compared to normal tissue^{30,31}. MSI is closely tied to the status of the mismatch repair (MMR) genes. In humans, the core MMR genes include MLH1, MSH2, MSH6, and PMS2³². Mutations and loss of expression in MMR genes,

Biomarker Descriptions (continued)

known as defective MMR (dMMR), lead to MSI. In contrast, when MMR genes lack alterations, they are referred to as MMR proficient (pMMR). Consensus criteria were first described in 1998 and defined MSI-high (MSI-H) as instability in two or more of the following five markers: BAT25, BAT26, D5S346, D2S123, and D17S250³³. Tumors with instability in one of the five markers were defined as MSI-low (MSI-L) whereas, those with instability in zero markers were defined as MS-stable (MSS)³³. Tumors classified as MSI-L are often phenotypically indistinguishable from MSS tumors and tend to be grouped with MSS^{34,35,36,37,38}. MSI-H is a hallmark of Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, which is caused by germline mutations in the MMR genes³¹. LS is associated with an increased risk of developing colorectal cancer, as well as other cancers, including endometrial and stomach cancer^{30,31,35,39}.

Alterations and prevalence: The MSI-H phenotype is observed in 30% of uterine corpus endothelial carcinoma, 20% of stomach adenocarcinoma, 15-20% of colon adenocarcinoma, and 5-10% of rectal adenocarcinoma^{30,31,40,41}. MSI-H is also observed in 5% of adrenal cortical carcinoma and at lower frequencies in other cancers such as esophageal, liver, and ovarian cancers^{40,41}.

Potential relevance: Anti-PD-1 immune checkpoint inhibitors including pembrolizumab⁴² (2014) and nivolumab⁴³ (2015) are approved for patients with MSI-H or dMMR colorectal cancer who have progressed following chemotherapy. Pembrolizumab⁴² is also approved as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR with disease progression on prior therapy who are not candidates for surgery or radiation. Importantly, pembrolizumab is approved for the treatment of MSI-H or dMMR solid tumors that have progressed following treatment, with no alternative option and is the first anti-PD-1 inhibitor to be approved with a tumor agnostic indication⁴². Dostarlimab⁴⁴ (2021) is also approved for dMMR recurrent or advanced endometrial carcinoma or solid tumors that have progressed on prior treatment and is recommended as a subsequent therapy option in dMMR/MSI-H advanced or metastatic colon or rectal cancer^{36,45}. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab⁴⁶ (2011), is approved alone or in combination with nivolumab in MSI-H or dMMR colorectal cancer that has progressed following treatment with chemotherapy. MSI-H may confer a favorable prognosis in colorectal cancer although outcomes vary depending on stage and tumor location^{36,47,48}. Specifically, MSI-H is a strong prognostic indicator of better overall survival (OS) and relapse free survival (RFS) in stage II as compared to stage III colorectal cancer patients⁴⁸. The majority of patients with tumors classified as either MSS or pMMR do not benefit from treatment with single-agent immune checkpoint inhibitors as compared to those with MSI-H tumors^{49,50}. However, checkpoint blockade with the addition of chemotherapy or targeted therapies have demonstrated response in MSS or pMMR cancers^{49,50}.

HLA-A deletion

major histocompatibility complex, class I, A

Background: The HLA-A gene encodes the major histocompatibility complex, class I, A¹. MHC (major histocompatibility complex) class I molecules are located on the cell surface of nucleated cells and present antigens from within the cell for recognition by cytotoxic T cells². MHC class I molecules are heterodimers composed of two polypeptide chains, α and B2M³. The classical MHC class I genes include HLA-A, HLA-B, and HLA-C and encode the α polypeptide chains, which present short polypeptide chains, of 7 to 11 amino acids, to the immune system to distinguish self from non-self^{4,5,6}. Downregulation of MHC class I promotes tumor evasion of the immune system, suggesting a tumor suppressor role for HLA-A⁷.

Alterations and prevalence: Somatic mutations in HLA-A are observed in 7% of diffuse large B-cell lymphoma (DLBCL), 4% of cervical squamous cell carcinoma and head and neck squamous cell carcinoma, 3% of colorectal adenocarcinoma, and 2% of uterine corpus endometrial carcinoma and stomach adenocarcinoma^{8,9}. Biallelic loss of HLA-A is observed in 4% of DLBCL^{8,9}.

Potential relevance: Currently, no therapies are approved for HLA-A aberrations.

Genes Assayed

Genes Assayed for the Detection of DNA Sequence Variants

ABL1, ABL2, ACVR1, AKT1, AKT2, AKT3, ALK, AR, ARAF, ATP1A1, AURKA, AURKB, AURKC, AXL, BCL2, BCL2L12, BCL6, BCR, BMP5, BRAF, BTK, CACNA1D, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD79B, CDK4, CDK6, CHD4, CSF1R, CTNNA1, CUL1, CYSLTR2, DDR2, DGCR8, DROSHA, E2F1, EGFR, EIF1AX, EPAS1, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, GATA2, GLI1, GNA11, GNAQ, GNAS, HIF1A, HRAS, IDH1, IDH2, IKBKB, IL6ST, IL7R, IRF4, IRS4, KCNJ5, KDR, KIT, KLF4, KLF5, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAPK1, MAX, MDM4, MECOM, MED12, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, MYO10, NFE2L2, NRAS, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, PAX5, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIM1, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, PXDN, RAC1, RAF1, RARA, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, ROS1, RPL10, SETBP1, SF3B1, SIX1, SIX2, SLC01B3, SMC1A, SMO,

Genes Assayed (continued)

Genes Assayed for the Detection of DNA Sequence Variants (continued)

SNCAIP, SOS1, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STAT6, TAF1, TERT, TGFB1, TOP1, TOP2A, TPMT, TRRAP, TSHR, U2AF1, USP8, WAS, XPO1, ZNF217, ZNF429

Genes Assayed for the Detection of Copy Number Variations

ABCB1, ABL1, ABL2, ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKC, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BLM, BMPR2, BRAF, BRCA1, BRCA2, BRIP1, CARD11, CASP8, CBF, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CREBBP, CSMD3, CTCF, CTLA4, CTNND2, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDR1, DDR2, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERRF1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FUBP1, FYN, GATA2, GATA3, GLI3, GNA13, GNAS, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, IDH2, IGF1R, IKBKB, IL7R, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KDR, KEAP1, KIT, KLF5, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LARP4B, LATS1, LATS2, MAGOH, MAP2K1, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MAX, MCL1, MDM2, MDM4, MECOM, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NCOR1, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NTRK1, NTRK3, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PCBP1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, PLAG1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPRT, PXDN, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RECQL4, RET, RHEB, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNF43, ROS1, RPA1, RPS6KB1, RPTOR, RUNX1, SDHA, SDHB, SDHD, SETBP1, SETD2, SF3B1, SLC1B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STAT6, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TERT, TET2, TGFB2, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TSC1, TSC2, U2AF1, USP8, USP9X, VHL, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZFH3, ZMYM3, ZNF217, ZNF429, ZRSR2

Genes Assayed for the Detection of Fusions

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

Genes Assayed with Full Exon Coverage

ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1, BCOR, BLM, BMPR2, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBF, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CIC, CIITA, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERCC2, ERCC4, ERCC5, ERRF1, ETV6, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, ID3, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MTAP, MTUS2, MUTYH, NBN, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPRT, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, RPA1, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOCS1, SOX9, SPEN, STAG2, STAT1, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFB2, TMEM132D, TNFAIP3, TNFRSF14, TP53, TP63, TPP2, TSC1, TSC2, UGT1A1, USP9X, VHL, WT1, XRCC2, XRCC3, ZBTB20, ZFH3, ZMYM3, ZRSR2

Relevant Therapy Summary

In this cancer type
 In other cancer type
 In this cancer type and other cancer types
 No evidence

PALB2 p.(T397Sfs*3) c.1190_1191delCA

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
talazoparib	×	×	×	×	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

HRR Details

Gene/Genomic Alteration	Finding
LOH percentage	10.69%
BRCA2	SNV, Y828H, AF:0.5
PALB2	LOH, 16p12.2(23614759-23652528)x2

Homologous recombination repair (HRR) genes were defined from published evidence in relevant therapies, clinical guidelines, as well as clinical trials, and include - BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L.

Thermo Fisher Scientific's Ion Torrent OncoPrint Reporter software was used in generation of this report. Software was developed and designed internally by Thermo Fisher Scientific. The analysis was based on OncoPrint Reporter (6.2.4 data version 2025.12(007)). The data presented here are from a curated knowledge base of publicly available information, but may not be exhaustive. FDA information was sourced from www.fda.gov and is current as of 2025-11-25. NCCN information was sourced from www.nccn.org and is current as of 2025-11-03. EMA information was sourced from www.ema.europa.eu and is current as of 2025-11-25. ESMO information was sourced from www.esmo.org and is current as of 2025-11-03. Clinical Trials information is current as of 2025-11-03. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers.' Variants are reported according to HGVS nomenclature and classified following AMP/ASCO/CAP guidelines (Li et al. 2017). Based on the data sources selected, variants, therapies, and trials listed in this report are listed in order of potential clinical significance but not for predicted efficacy of the therapies.

References

1. O'Leary et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* 2016 Jan 4;44(D1):D733-45. PMID: 26553804
2. Hulpke et al. The MHC I loading complex: a multitasking machinery in adaptive immunity. *Trends Biochem Sci.* PMID: 23849087
3. Adams et al. The adaptable major histocompatibility complex (MHC) fold: structure and function of nonclassical and MHC class I-like molecules. *Annu Rev Immunol.* 2013;31:529-61. PMID: 23298204
4. Rossjohn et al. T cell antigen receptor recognition of antigen-presenting molecules. *Annu Rev Immunol.* 2015;33:169-200. PMID: 25493333
5. Parham. MHC class I molecules and KIRs in human history, health and survival. *Nat Rev Immunol.* 2005 Mar;5(3):201-14. PMID: 15719024
6. Sidney et al. HLA class I supertypes: a revised and updated classification. *BMC Immunol.* 2008 Jan 22;9:1. PMID: 18211710
7. Cornel et al. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. *Cancers (Basel).* 2020 Jul 2;12(7). PMID: 32630675
8. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
9. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
10. Xia et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Mol. Cell.* 2006 Jun 23;22(6):719-29. PMID: 16793542
11. Niraj et al. The Fanconi Anemia Pathway in Cancer. *Annu Rev Cancer Biol.* 2019 Mar;3:457-478. PMID: 30882047
12. Lord et al. BRCAness revisited. *Nat. Rev. Cancer.* 2016 Feb;16(2):110-20. PMID: 26775620
13. Byrum et al. Defining and Modulating 'BRCAness'. *Trends Cell Biol.* 2019 Sep;29(9):740-751. PMID: 31362850
14. Michl et al. Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. *EMBO J.* 2016 May 2;35(9):909-23. PMID: 27037238
15. Abbasi et al. A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population. *Mol Med Rep.* 2017 Jun;15(6):3983-3988. PMID: 28440412
16. Tischkowitz et al. PALB2/FANCN: recombining cancer and Fanconi anemia. *Cancer Res.* 2010 Oct 1;70(19):7353-9. PMID: 20858716
17. Reid et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nat. Genet.* 2007 Feb;39(2):162-4. PMID: 17200671
18. Rahman et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat. Genet.* 2007 Feb;39(2):165-7. PMID: 17200668
19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf
20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217439s003lbl.pdf
21. Mateo et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *N. Engl. J. Med.* 2015 Oct 29;373(18):1697-708. PMID: 26510020
22. Goodall et al. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. *Cancer Discov.* 2017 Sep;7(9):1006-1017. PMID: 28450425
23. D'Andrea. Mechanisms of PARP inhibitor sensitivity and resistance. *DNA Repair (Amst.).* 2018 Nov;71:172-176. PMID: 30177437
24. Horak et al. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. *Cold Spring Harb Mol Case Stud.* 2019 Apr;5(2). PMID: 30833416
25. Seed et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. *Cancer Cell.* 2024 Dec 9;42(12):2113-2123.e4. PMID: 39577422
26. Zong et al. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients. *J Cancer.* 2022;13(4):1119-1129. PMID: 35281878
27. <https://www.senhwabio.com/en/news/20220125>
28. NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 2.2025]
29. Lander et al. Initial sequencing and analysis of the human genome. *Nature.* 2001 Feb 15;409(6822):860-921. PMID: 11237011
30. Baudrin et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer. *Front Oncol.* 2018 Dec 12;8:621. doi: 10.3389/fonc.2018.00621. eCollection 2018. PMID: 30631754
31. Nojadedh et al. Microsatellite instability in colorectal cancer. *EXCLI J.* 2018;17:159-168. PMID: 29743854

References (continued)

32. Saeed et al. Microsatellites in Pursuit of Microbial Genome Evolution. *Front Microbiol.* 2016 Jan 5;6:1462. doi: 10.3389/fmicb.2015.01462. eCollection 2015. PMID: 26779133
33. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* 1998 Nov 15;58(22):5248-57. PMID: 9823339
34. Halford et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. *Cancer Res.* 2002 Jan 1;62(1):53-7. PMID: 11782358
35. Imai et al. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. *Carcinogenesis.* 2008 Apr;29(4):673-80. PMID: 17942460
36. NCCN Guidelines® - NCCN-Colon Cancer [Version 5.2025]
37. Pawlik et al. Colorectal carcinogenesis: MSI-H versus MSI-L. *Dis. Markers.* 2004;20(4-5):199-206. PMID: 15528785
38. Lee et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. *Medicine (Baltimore).* 2015 Dec;94(50):e2260. PMID: 26683947
39. Latham et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J. Clin. Oncol.* 2019 Feb 1;37(4):286-295. PMID: 30376427
40. Cortes-Ciriano et al. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun.* 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180. PMID: 28585546
41. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol.* 2017;2017. PMID: 29850653
42. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf
43. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s131lbl.pdf
44. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf
45. NCCN Guidelines® - NCCN-Rectal Cancer [Version 4.2025]
46. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s136lbl.pdf
47. Ribic et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N. Engl. J. Med.* 2003 Jul 17;349(3):247-57. PMID: 12867608
48. Klingbiel et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. *Ann. Oncol.* 2015 Jan;26(1):126-32. PMID: 25361982
49. Hermel et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. *J Pers Med.* 2019 Jan 16;9(1). PMID: 30654522
50. Ciardiello et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev.* 2019 Jun;76:22-32. PMID: 31079031